Review pending. Every figure has been located on its cited source page in an AI-assisted source verification (matched to the document's text) (9 October 2026). Independent review has not yet been carried out, and these pages are not indexed.AI-assisted source check done; independent review pending; not indexed. About the review
Neimeth
On this page
Company details
- Legal name
- Neimeth International Pharmaceuticals Plc
- Listing
- NEIMETH on the Nigerian Exchange, active · ISIN NGNEIMETH001 (observed 2026-10-08)
- Sector
- Not classified (our classification from the stated principal activity)
- Financial year ends
- 31 December
Overview
Year ended 31 December 2025 · audited financial statements, signed / final · source
-
Revenue
NGN 7.37 billion
7,368,524 NGN thousands · p18
+64.3% vs 2024
-
Operating profit / (loss)
NGN 2.63 billion
2,634,972 NGN thousands · p18
+13852.0% vs 2024
-
Profit / (loss) for the year
NGN 976 million
976,417 NGN thousands · p18
Moved from loss to profit (FY2024: (885,333) NGN thousands)
-
Total assets
NGN 14.0 billion
14,014,101 NGN thousands · p19
+16.9% vs 2024
-
Total equity
NGN 2.63 billion
2,628,209 NGN thousands · p19
+59.1% vs 2024
-
Cash from operations
NGN 1.51 billion
1,507,437 NGN thousands · p21
+280.5% vs 2024
Large amounts are rounded for reading (NGN million / billion / trillion); exact figures as printed are under each amount and in the tables. No currency conversion.
Financial statements
Exact figures as printed. Each column comes from one filing; labels are as printed in the newest filing. Amounts in NGN thousands unless the row says otherwise; brackets are negative.
† from a supplementary filing for the same year · ‡ signed audited statements preferred over a disputed figure · “–” is a printed dash, explained below the table
Column sources
- FY2025 — audited financial statements, signed / final; reported for the year · source
- FY2024 — audited financial statements, signed / final; comparative in the FY2025 filing · source
Income statement
| Line (as printed) | FY2025Audited financial statementsreported for the year | FY2024Audited financial statementscomparative in FY2025 filing |
|---|---|---|
| Revenue | 7,368,524 | 4,485,116 |
| Cost of sales | (4,298,515) | (2,527,394) |
| Gross profit | 3,070,009 | 1,957,722 |
| Other operating income | 1,186,623 | 1,417,748 |
| Marketing and distribution expenses | (927,218) | (680,453) |
| Administrative expenses | (909,291) | (628,176) |
| Foreign exchange gain/(loss) | 214,849 | (2,047,955) |
| Operating profit | 2,634,972 | 18,886 |
| Finance costs | (1,322,058) | (873,320) |
| Profit/(loss) before taxation | 1,312,914 | (854,434) |
| Income tax expense | (336,497) | (30,899) |
| Profit/(loss) for the year | 976,417 | (885,333) |
| Total other comprehensive income for the year | –1 | –1 |
| Total comprehensive income/(loss) | 976,417 | (885,333) |
- Printed “-”, read as nil: subtotal_arithmetic: is.total_comprehensive_income.
Balance sheet
| Line (as printed) | FY2025Audited financial statementsreported for the year | FY2024Audited financial statementscomparative in FY2025 filing |
|---|---|---|
| Property, plant and equipment | 4,263,128 | 4,209,211 |
| Investment property | 2,775,526 | 2,024,585 |
| Intangible assets | 9,501 | 19,003 |
| Non-current assets (unlabelled subtotal) | 7,048,155 | 6,252,799 |
| Inventories | 3,894,393 | 1,868,341 |
| Trade and other receivables | 1,342,460 | 1,616,290 |
| Other assets | 174,230 | 103,395 |
| Cash and cash equivalents | 1,554,863 | 2,146,658 |
| Current assets (unlabelled subtotal) | 6,965,946 | 5,734,684 |
| Total assets | 14,014,101 | 11,987,483 |
| Trade and other payables | 959,115 | 4,350,944 |
| Bank overdraft | –1 | 201,988 |
| Current portion of long term borrowings | 2,652,518 | 4,859,136 |
| Finance lease liabilities | 10,516 | 28,789 |
| Current tax payable | 111,427 | 87,228 |
| Deferred fair value gain on loan2 | 78,614 | 90,023 |
| Current liabilities (unlabelled subtotal) | 3,812,190 | 9,618,108 |
| Non-current portion of long term borrowings | 6,955,111 | 294,672 |
| Deferred fair value gain on loan3 | 238,071 | 316,685 |
| Deferred tax liability | 380,520 | 106,226 |
| Non-current liabilities (unlabelled subtotal) | 7,573,702 | 717,583 |
| Total liabilities | 11,385,892 | 10,335,691 |
| Share capital | 2,136,552 | 2,136,552 |
| Share premium | 2,377,756 | 2,377,756 |
| Accumulated losses | (1,886,099) | (2,862,516) |
| Total equity | 2,628,209 | 1,651,792 |
- Printed “-”, read as nil: subtotal_arithmetic: bs.current_liabilities.
Notes and alternative reported figures (2)
- “Deferred fair value gain on loan” is an issuer-specific line, not mapped to a shared definition: Note 24.1: deferred day-one fair value gain on a below-market loan, current portion.
- “Deferred fair value gain on loan” is an issuer-specific line, not mapped to a shared definition: Note 24.2: deferred day-one fair value gain on a below-market loan, non-current portion.
Cash flow
| Line (as printed) | FY2025Audited financial statementsreported for the year | FY2024Audited financial statementscomparative in FY2025 filing |
|---|---|---|
| Operating cash flow before working-capital changes (unlabelled subtotal)1 | 6,760,327 | (768,885) |
| Cash generated from operating activities | 1,545,441 | 408,694 |
| Income tax paid | (38,004) | (12,486) |
| Net cash generated from operating activities | 1,507,437 | 396,208 |
| Purchase of property, plant and equipment | (278,234) | (702,919) |
| Proceeds from disposal of property, plant and equipment | 6,961 | 3,600 |
| Net cash used in investing activities | (271,273) | (699,319) |
| Repayment of loans | (125,001) | (50,000) |
| Finance cost paid2 | (1,315,528) | (866,790) |
| Finance lease liabilities3 | (18,273) | (11,846) |
| Net cash used in financing activities | (1,458,802) | (928,636) |
| Net increase/(decrease in cash and cash equivalents | (222,638) | (1,231,747) |
| Cash and cash equivalents at the beginning of the period | 1,944,670 | 2,252,834 |
| Effect of exchange rate changes on cash and cash equivalents | (167,169) | 923,583 |
| Cash and cash equivalents at the end of the year | 1,554,863 | 1,944,670 |
Notes and alternative reported figures (3)
- “Operating cash flow before working-capital changes (unlabelled subtotal)” is an issuer-specific line, not mapped to a shared definition: Printed unlabelled subtotal of profit and adjustments, before 'Changes in:'.
- “Finance cost paid” is an issuer-specific line, not mapped to a shared definition: Financing activities (note 14).
- “Finance lease liabilities”: mapping to a shared definition is uncertain. Printed 'Finance lease liabilities' under financing activities: lease payments.
Segments
Segment data not yet collected for this company in the pilot.
Dividends
Proposed or recommended, declared and paid are different events and are kept apart. A statement that no dividend was proposed does not mean none was paid.
No dividend statement or amount collected.
Sources
Each filing used on this page, newest period first. Dates are the document's own; the date we retrieved a file is shown separately and is never a publication date.
-
Neimeth International Pharmaceuticals Plc Financial Statements 31 December 2025
Year ended 31 December 2025 · Audited financial statements · signed / final
Audit: BDO Professional Services (Chartered Accountants), Lagos, unmodified opinion · signed
Auditor's sign-off: Olugbemiga A. Akibayo, FCA, for BDO Professional Services
Final status: Independent auditor's report to the shareholders of Neimeth International Pharmaceuticals Plc (PDF pp15-17; opinion p15), unmodified, signed by hand above 'Olugbemiga A. Akibayo, FCA, FRC/2013/PRO/ICAN/004/00000001076, For: BDO Professional Services, Chartered Accountants', 'Lagos, Nigeria, 29 March 2026', with the ICAN seal (p17, page image). Statements 'approved and authorised for issue by the Board of Directors on 27 March 2026', with handwritten signatures of Mr. Christopher Oshiafi (Chairman), Pharm. Valentine C. Okelu (Managing Director / CEO) and Mrs. Nonye E. Offorjamah (Head of Finance) (p19, page image).
- Document date
- 29 Mar 2026
- Auditor's report
- 29 Mar 2026
- Board approval
- 27 Mar 2026
- Retrieved by us
- 8 Oct 2026 (not a publication date)
- Used for
- statement columns FY2025, FY2024
- Basis
- company statements · NGN thousands (printed “N'000”)
- HIDDEN TEXT-LAYER ROW: the text layer of p19 holds a non-current 'Finance lease liabilities 30' row with '-' in both years, after 'Non-current portion of long term borrowings'; the printed page shows no such row (page image). No hidden figure differing from the printed page was found; the hidden row is not transcribed.
- Key audit matters (pp15-16): valuation of trade receivables (expected credit loss) and valuation of investment property. PDF p14 is BDO's separate assurance report on internal control over financial reporting.
- The cash-flow statement's first line is labelled 'Profit/ (loss) for the year' but prints 1,312,914 (2024: (854,434)), which is profit before taxation on p18 (p21). The statement of financial position presents 'Net assets' and total equity; no 'total equity and liabilities' line is printed (p19).
- EPS printed in kobo: basic 23 (2024: (21)); diluted printed identically (note 33, p18); stored in naira with the printed figure and unit kept.
Technical details
- File
- 66 pages, with a text layer
- SHA-256
2d5d0f64a117be677a363ac8300ad85a506c12925a3255630e2aa8888d9540e0- Entity as printed
- NEIMETH INTERNATIONAL PHARMACEUTICALS PLC
- Exchange copy
- retrieved 2026-10-08T17:55:59Z
Data notes
No figure-level notes beyond those in the tables.
Review status: every figure has been located on its cited source page in an AI-assisted source verification (matched to the document's text) (9 October 2026). Independent review is pending for every figure; automated checks and the AI-assisted verification are not independent review.
Download
Figures shown on this page (CSV) — the same selected figures at their exact printed values, each with its source document, SHA-256, page, selection rule and reading. Independent review of these figures is pending.